Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW402 Multiple Ascending Dose Study in Healthy Volunteers
NCT07546149Phase 1Completed
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lw402 (6 arms), sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. Primary endpoint: Safety and Tolerability Assessment at 9 days. Started Oct 2025; status: completed.
02
Drugs
lw402
Beyond the preview
Go deeper on NCT07546149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546149.